DRAXXIN was specifically developed for use in livestock. A series of studies performed to evaluate the safety of DRAXXIN revealed:
- A wide margin of safety, tested up to 10x in cattle and swine.
- Some transient discomfort, primarily observed as head shaking in cattle safety studies.
- Preslaughter withdrawal time of 18 days in cattle.
- Also, approved for use in swine.
- Do not use DRAXXIN in dairy heifers 20 months of age or older. Do not use in calves to be processed for veal. Effects on reproductive performance,
pregnancy and lactation have not been determined.
Unique chemistry and a highly convenient formulation put DRAXXIN in a subclass of its own among leading BRD therapies. DRAXXIN offers:
- Superior efficacy to treat BRD when compared with Baytril®, Nuflor® and Micotil® in field studies.1,2,3,6
- Convenient, full course of therapy in a single dose.
- Effectiveness against the four major BRD pathogens.
- Mannheimia (Pasteurella) haemolytica
- Pasteurella multocida
- Histophilus somni (Haemophilus somnus)
- Mycoplasma bovis
- Excellent first BRD treatment response.1,2,3,6
- Remarkably lower mortalities and chronics due to BRD.1,2,3
- Effective control of BRD in cattle at high risk of developing BRD.3
To learn more about how DRAXXIN can deliver healthier cattle and a healthier bottom line for your business, contact your Pfizer representative, your
veterinarian, animal health supplier, or call 1-888-DRAXXIN.
< Previous | Next - News >